In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...